anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

235,621-235,680 of 319,975

filter-aware
01
Slide 1
Amazon | Results Presentation Deck | 19 slidesAmazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
02
Amazon | Results Presentation Deck | 19 slidesAmazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
03
The slide includes a footnote regarding F/X adjusted figures.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
04
The bar chart shows growth over five quarters, while the pie chart shows the composition of net sales.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
05
The chart shows a dip in Q2 2024 compared to Q1 2024, followed by strong growth in Q3 and Q4.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
06
The chart displays a clear upward trend in operating income over five consecutive quarters.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
07
The chart displays five data points representing quarterly net income in millions.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
08
Amazon | Results Presentation Deck | 19 slidesAmazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
09
Amazon | Results Presentation Deck | 19 slidesAmazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
10
TTM = Trailing Twelve Months. F/X = Foreign Exchange.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
11
TTM = Trailing Twelve MonthsAmazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
12
The chart highlights a 4% year-over-year increase in FCF, with a footnote clarifying that operating cash flow increased 36% Y/Y.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
13
The chart tracks a specific non-GAAP financial metric over five quarters.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
14
The chart highlights a 2% year-over-year growth in this specific non-GAAP metric.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
15
The chart highlights the trend in share dilution over five quarters.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
16
Amazon | Results Presentation Deck | 19 slidesAmazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
17
Values are in millions (MM).Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
18
TTM stands for Trailing Twelve Months, though the table presents discrete quarterly data points.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
19
TTM stands for Trailing Twelve Months. The table reconciles Operating Cash Flow to a specific adjusted Free Cash Flow metric.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
01
Slide 1
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
02
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
03
The slide uses a three-column layout to summarize key strategic pillars: clinical assets, development timeline, and platform pedigree.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
04
The slide uses a hub-and-spoke diagram to connect Boron to four therapeutic areas (Oncology, Inflammatory Response, Parasites, Bacterial Diseases).AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
05
The slide uses a Gantt-style chart to show the development stage of multiple drug candidates.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
06
The slide uses a timeline-based framework to categorize R&D milestones and market opportunities.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
07
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
08
The slide combines a problem statement (clinical unmet need) with a market sizing chart.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Market Size1 hit
09
Includes clinical trial timeline diagram and outcome tables.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Market Size1 hit
10
The table uses blue highlighting to emphasize the higher severity metrics in the EBO Ph 2 group.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
11
LSM = Least squares mean. PRO = Patient-Reported Outcome. The slide highlights alignment with FDA guidance for primary endpoints in NTM trials.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
12
The chart highlights a statistically significant improvement (p=0.036) at month 6.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Voice Of Customer1 hit
13
The chart shows a longitudinal comparison of two treatment groups over 6 months. The p-value of 0.043 indicates nominal statistical significance for the difference in mean change from baseline.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Voice Of Customer1 hit
14
The slide presents TEAE (Treatment-emergent adverse events) and SAE (Serious adverse events) data.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
15
Focuses on PRO (Patient Reported Outcomes) as a primary endpoint for the EBO-301 trial.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
16
The slide presents three line charts (A, B, C) comparing PBS, IMI (Imipenem), and two doses of EBO (EBO25, EBO50) over 4 weeks.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
17
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
18
Includes a map showing global distribution and a specific callout for US endemicity.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
19
The slide uses a central hub-and-spoke style diagram to connect funding sources with market potential.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
20
The chart shows Log10 CFU counts in lungs for various treatment groups compared to untreated control.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
21
The slide uses a dual-track timeline approach to show the progression from observational data collection to clinical trial phases.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
22
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
23
Includes a disease progression timeline diagram on the right.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
24
The slide uses a hub-and-spoke diagram to show the global burden relative to specific regions.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
25
The slide uses a dot map to visualize geographic distribution of infections.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
26
Includes chemical structure of the benzoxaborole molecule.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
27
The chart demonstrates superior efficacy of the lead compound over existing treatments (Benznidazole and E1224) in a model that mirrors human clinical outcomes.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
28
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
29
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
30
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
31
The slide uses a hub-and-spoke diagram to connect Boron to various medical fields, with a specific callout to oncology applications.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
32
The slide uses a hub-and-spoke diagram to connect the central Boron element to four therapeutic areas, then links to specific development programs.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
33
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Team1 hit
34
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Team1 hit
35
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
36
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
01
Slide 1
AstraZeneca | Results Presentation Deck | 42 slidesAstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Attention1 hit
02
AstraZeneca | Results Presentation Deck | 42 slidesAstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Attention1 hit
03
AstraZeneca | Results Presentation Deck | 42 slidesAstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Attention1 hit
35
Standard Tesla investor relations disclosure page.Tesla | Results Presentation Deck | 36 slides · Tesla
Conference presentation Investor relations Beat · Action1 hit
36
Tesla | Results Presentation Deck | 36 slidesTesla | Results Presentation Deck | 36 slides · Tesla
Conference presentation Investor relations Beat · Action1 hit